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Summary.-The presence of a tumour-associated immune response in 37 patients
with ovarian cancer as assessed by blastogenesis (lymphocyte transformation)
evoked by ovarian cancer cell extracts, has been correlated with survival following
the test. The difference in these responses is unlikely to be accounted for on the
basis of general impairment of cell-mediated immuno-competence.
Serum carcinoembryonic antigen (CEA) was also determined in27 ovarian cancer
patients to assess its prognostic significance. Raised CEA levels and absence of
blastogenic response to tumour cell extract during relapse are associated with a
worse prognosis but neither of these parameters are significant in remission.
Possible applications of these findings to the clinical management of ovarian
cancer patients are discussed.
Serum alpha feto-protein levels measured by radioimmunoassay were not
found to be raised in any of the 32 ovarian cancer patients in whom it was measured.
ANERGY to secondary recall antigens
in cancer patients has been associated
with a bad prognosis. Patients with
adult leukaemia who are anergic to
secondary recall antigens in vivo before
induction of remission are reported to
have a worse prognosis than those who
respond to at least one out of 5 recall
antigens (Hersh et al., 1974). Eilber and
Morton (1970) also showed that 930
of patients with solid tumours who did
not develop primary skin responses to
dinitrochlorobenzene preoperatively were
either inoperable or developed early tu-
mour recurrence.
We have recently reported that ovarian
cancer patients show in vitro evidence
of sensitization to determinants present
in ovarian cancer cell extracts, and that
this occurs more often in remission than
during relapse (Levin et al., 1975a). We
are now able to correlate these blastogenic
responses to ovarian cancer cell extract
(OCE) with subsequent short term sur-
vival.
Raised levels of CEA have been
found in ovarian cancer patients (Di
Saia et al., 1975; Barrelet and Mach,
1975; van Nagell et at., 1975; Seppala,
Pihko and Rouslahti, 1975). Patients
in relapse have been shown to have
generally higher levels. CEA was mea-
sured in most of the patients in this
series so that evidence of the relationship
of these isolated levels to survival is
likewise available. The patients' serum
was also screened for raised levels of
alpha feto-protein (AFP).
METHOD AND MATERIALS
The ovarian cancer cell extract (OCE)
from common epithelial tumours was pre-
pared, and lymphocyte cultures were set up,
as previously described (Levin et al., 1975a);L. LEVIN ET AL.
and 106 mononuclear cells, mnostly lympho-
cytes, were stimulated with 100 jtg of OCE.
After incubating at 37 C in 50o C02, for
5 days the extent of transformation wAas
assessed by subtracting the radioactive
incorporation of 125IUDR (5-iodo-2-deoxy-
uridine) by unchallenged lymphocytes from
that of challenged lymphocytes (et/min
difference). From previous data (Levin et
al., 1975a) patients with a ct/min difference
greater than 500 (stimulation index, S.I.
> 1-2) were regarded as having a blastogenic
response to OCE, since none of the 18
controls had a blastogenic response greater
than this.
CEA wias measured by a double antibody
radioimmunoassay method of Egan et al.
(1972) and modified by using a single label
(1251-CEA) as described by Laurence et al.
(1972). AFP was measured by a radio-
immunoassay method as described by Leek
and Chard (1974); highly purified AFP was
used in this assay and polyethylene glycol
used for separation ofbound and free antigen.
The tumour histology was reviewed in
the Williamson Laboratory as part of an
on-going research programme (Curling and
Hudson, 1975).
Patients
Definitive staging of new cases according
to the criteria of the International Federa-
tion of Gynaecology and Obstetrics (FIGO)
was made at operation (Table I). Nearly
all patients wiere treated with chemotherapy
involving the use of at least one alkylating
agent. Two patients received experimental
immunotherapy, details of w%Nhich are re-
ported elsewhere (Levin et al., 1974).
Patients in remission had no evidence
of persistent or active disease following
surgery with or without adjuvant therapy
and had had no treatment for 30 days prior
to testing.
Patients referred to as being in relapse
had active disease spread beyond the ovary.
The blastogenic reponse to tumour ex-
tract was assessed in 21 remission patients,
CEA assayed in 20 remission patients and
AFP in 13 remission patients.
The testing and survival time in patients
with recurrent disease refers only to the
period under observation. Blastogenic re-
sponses to tumour extract were assessed
in 16 relapse patients, CEA assayed in
23 relapse patients and AFP in 19 relapse
patients.
Patients in i-emission and relapse who
died of causes unrelated to their tumour
wNere not included in this series.
The 18 controls in whom CEA was
measured, were all healthy non-pregnant
females, matched for age with the ovarian
cancer patients and most were awaitiing
elective surgery for prolapse repair.
RESULTS
Blastogenic assay
Individual survival times for relapse
and remission patients are shown in
Fig. 1 and 2 respectively.
(a) Relapse patients. Six out of 8
(7500) relapse patients who failed to
demonstrate a response to OCE prior to
treatment were dead within 6 months of
the test being performed, the median
survival being 3-5 months (range 1-12
months). Both patients who survived
for more than 6 months in this group
were on immunotherapy for ovarian
cancer.
Conversely all 8 relapse patients
(100%) who demonstrated a blastogenic
response to OCE were alive after 6
months; two have subsequently relapsed
after 12 and 15 months, 3 are well but
with quiescent disease and 3 are disease
free. The median survival for this group
is l2-5 months (range 7-18 months). This
difference is significant at the 300 level
(Fisher's exact probability test).
The median age of relapse responders
was 60 years (range 51-68) and the
median age of relapse non-responders was
59 years (range 38-72).
Data relating to tumour staging and
histological types in relapse responders
and non-responders are presented in
Table I. Six out of 8 relapse responders
and 5 out of 8 relapse non-responders
had serious papillary cystadenocarcinoma.
In no patient was the histological classi-
fication of low potential malignancy and
one of the three patients whose tumour
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FIG. 1. Survival in relapse responders vs non-responders.
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Fia. 2. Survival in remission responders vs non-respon(lers.
was well differentiated is already dead
from recurrent disease.
In terms of FIGO staging there is a
minor difference between the responding
and non-responding groups. Neverthe-
less there is a substantial overlap of
comparable cases in the two groups and
in these no distinction may be made.
(b) Remiis8ion patients.-The 6 remis-
sion patients who did not demonstrate
blastogenic responses to OCE and 15
remission patients who did are all alive
Number of
Patients
2
Responders
Non-
Responders 2
Number of
Patients
Responders
Non-
Responders
a I i
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TABLE I.-Comparison of Histological Types and Extent of Tumour Spread in Relapse
Responders and Non-Responders
Responders
(S.I. > 1-2 an(d ct/min (lifference > 500)
_ __ ____--
Non-responders
(S.I. < 1 2 aind et/min dlifference < 500)
Tumour histology
Serous papillary
Serous papillary
Endometrioid
Serous papillary
Serous papillary
Serous papillary
Endometrioid with serous
papillary elements
Serous papillary
Stage
Tl
II
III
III
III
Recurrent disease
Recurient disease
Rectuirrent disease
Tumour histology
Serous papillary
Serous papillary
Serous papillary
Serous papillary
Serous papillary
Endometrioid
Mlucinous cystadenocarcinoma
Mesonephroid
Stage
III
III
III
IV
IV
Recurrent (lisease
Recurrent disease
Recurrent dlisease
6 months after the test, the median
survival being 16 months (range 7-18
months). A qualitative assessment of
blastogenesis in remission responders
showed that the best responses occurred
in patients who had been in remission
for less than 24 months.
Carcinoembryonic antigen assay
Serum CEA levels are shown on the
scatter graph (Fig. 3) for ovarian cancer
patients in relapse and in remission, and
for normal controls matched for age
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and sex. Survival times following CEA
measurement are shown in Fig. 4. Only
patients who could be followed up for
6 months or more are shown.
(a) Relapse patients. None of the 5
relapse patients with elevated CEA levels
was alive after 6 months whereas 6 out
of 8 relapse patients with normal CEA
levels were alive. All relapse patients
with raised CEA levels were found to
have disease spread beyond Stage II.
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(b) Remission patients. All patients
in remission tested for CEA were alive
6 months after testing regardless of whe-
ther the levels were raised or not.
Alphafeto-protein acssay
The upper limit in normal non-
pregnant females, using this assay is
25 ng/ml (Rouslahti and Seppala, 1972).
None of the 32 ovarian cancer patients
in whom AFP was measured had raised
levels; the median level was 9 5 ng/ml
and the range was 0 8-19 ng/ml.
DISCUISSION
An impaired in vitro tumour-associated
cell-mediated immmune response during
relapse appears to be associated with
a poor prognosis, most of the patients
dying within 6 months of the test being
performed. Of interest is the fact that
the longest surviving patient in this
group was on immunotherapy and she
survived for 12 months. The other pa-
tient on immunotherapy, who has been
followed up for only 8 months so far, is
alive with quiescent disease.
All 8 relapse patients who demon-
strated a blastogenic reponse to OCE
are alive 6 months after the test.
There is no evidence that the difference
in results between relapse responders and
non-responders could be accounted for
on the basis of age distribution in these
groups or on the basis of histological
types of tumour. While there is evidence
for some correlation between tumour
load and tumour-associated immune re-
sponse this clearly will not account for
the difference between the two groups.
In data not yet published we have
found that while ovarian cancer patients
do not have an impaired blastogenic
response to PPD, responses to PHA are
reduced in relapse patients. Both PHA
and PPD induce predominantly T-cell
blastogenesis (Kreeftenberg, Leerling and
Loggen, 1975), but the response to PPD
probably follows more closely the mech-
anism ofthe response to tumour-associated
antigen in this system, since PHA is
a powerful mitogen which requires no pre-
sensitization to induce blastogenesis
whereas PPD and (one would assume)
tumour-associated antigens do. We sus-
pect therefore that impaired cell-mediated
immunity was not necessarily responsible
for the difference in the tumour-associated
immune response between remission and
relapse groups, and within the relapse
group of patients.
In patients in remission there is no
correlation between impaired blastogenic
response to OCE and subsequent survival.
One remission non-responder had been
in remission for 5 years and another for
8 years before assessing blastogenesis.
The lack of response in these two patients
might be attributed to decreased recogni-
tion of tumour antigens after this period
of time and this is supported by the fact
that the best responses in remission
patients were seen when duration of
remission was less than 24 months.
Raised serum CEA levels in relapse
patients also appear to have some prog-
nostic significance but raised levels in
remission are of questionable significance.
Normal levels of CEA in relapse patients
may reflect a better prognosis but atten-
tion is drawn to the fact that 2 out of 8
patients in relapse with normal CEA
levels died within 6 months of the test
being performed and in one of these
patients no evidence of tumour-associated
immunity could be found at the time
of testing. Raised CEA levels in relapse
appears to reflect the extent of disease.
Laurence et al. (1972) found that
using this CEA assay, only levels above
40 ng/ml were diagnostic of cancer, and
lower levels could have been due to other
factors such as regenerative diseases and
non-specific inflammation. None of the
remission patients in this series had
levels raised above 40 ng/ml but while
CEA levels between 23-40 ng/ml appear
to have no prognostic significance in
remission, two relapse patients with levels
in this range died of progressive disease
after 1 month and 6 months.
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The question whether the blastogenic
assay might be assessing CEA has been
considered; Lejtenyi, Freedman and Gold
(1971) found that CEA was incapable
of giving rise to blastogenesis. In one
of our tumour extracts at a concentration
of 2 mg/ml no evidence of CEA could
be detected by radioimmunoassay.
Clinical implications
Barrelet and Mach (1975) have shown
that high CEA levels in ovarian cancer
relapse patients will fall to normal levels
with adequate treatment. We have now
shown that it is possible to produce a
tumour-associated cell-mediated immune
response in ovarian cancer patients by
inoculating them with ovarian cancer
cells (Levin et al., 1975c).
It remains to be seen whether special
therapeutic attention to an identified
group with elevated CEA and/or no
evidence of a blastogenic response to
tumour extract can improve the salvage
rate, and indeed whether the addition
of immunotherapy can help the latter
group or whether its preferred role would
be rather to boost the response of those
patients still capable of mounting a
tumour-associated cell-mediated immune
response.
Cyonclussion
In vitro evidence of tumour-associated
immunity, assessed by lymphocyte trans-
formation appears to be an important
parameter in assessing the prognosis of
ovarian cancer patients in relapse but
not for patients in remission from disease.
Increased length of remission is partly
responsible for decreased or nil responses
in remission patients. These responses
appear to be independent of the cell-
mediated immune response measured by
blastogenesis to PPD.
CEA estimations in ovarian canicer
patients appear to have a prognostic
-value only if raised in relapse. Raised
CEA levels were seen in all relapse
patients who died within 6 months of the
test beiing performed. Raised CEA levels
in remission patients had no prognostic
significance though none of these levels
were excessively raised.
Patients with ovarian cancer present-
ing with high CEA levels and without
evidence of a tumour-associated cell-
mediated immune response would appear
to have a poor prognosis, unless more
aggressive therapy than is usual at present
can be shown to reverse the process.
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